Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $115 to $120.
Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $115 to $120.